GREY:IMVIQ - Post by User
Comment by
Hideawayon Nov 06, 2019 11:58am
104 Views
Post# 30316068
RE:RE:RE:Updated Results from Phase 2 SPiReL Study Evaluating IMV’s D
RE:RE:RE:Updated Results from Phase 2 SPiReL Study Evaluating IMV’s D Based on June 1st release, the enrollment target is 28 patients. In that NR they indicated 19 had been enrolled to date, with 7 evaluable.
In the Aug.8th financial results release they indicated the following:"
We have enrolled 16 additional patients in the expanded monotherapy arm of the DeCidE1 trial. IMV expects to provide the top-line clinical results from this study before the end of 2019." This would bring total to 23 enrolled as of Aug 8th
Not sure how long it takes to start evaluating patients,but, if Qwerty's calculations hold, it would appear as only one additional patient was added to the 7 evaluated in the June 1st release.
GLTA